The Transcatheter Pulmonary Valve (TPV) is a type of cardiovascular device used to treat congenital heart defects. It is a minimally invasive procedure that replaces a damaged pulmonary valve with a new one. The TPV is inserted through a catheter, which is inserted through a vein in the leg and guided to the heart. The procedure is used to treat pulmonary valve stenosis, a condition in which the pulmonary valve does not open properly, leading to a decrease in blood flow to the lungs. The TPV market is a rapidly growing segment of the cardiovascular device market. It is expected to benefit from the increasing prevalence of congenital heart defects, technological advancements, and the growing demand for minimally invasive procedures. The market is also expected to benefit from the increasing number of clinical trials and the growing number of regulatory approvals. Some of the major companies in the Transcatheter Pulmonary Valve market include Edwards Lifesciences, Medtronic, Boston Scientific, Abbott, and St. Jude Medical. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
